Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31

What Was Tested

This randomized controlled trial paper looks at Goserelin.

Although androgen suppression results in a tumor response/remission in the majority of patients with carcinoma of the prostate, its potential value as an adjuvant has not been substantiated.

Who Took Part

The study group was 977 patients.

PubMed tags the participants as men only.

In 1987, the Radiation Therapy Oncology Group (RTOG) initiated a randomized phase III trial of adjuvant goserelin in definitively irradiated patients with carcinoma of the prostate.

A total of 977 patients had been accessioned to the study.

How the Study Was Run

In design terms this was a randomized study.

The patients were allocated by chance, so the Goserelin group and the comparison group should start out alike.

Of these, 945 remained analyzable: 477 on the adjuvant arm and 468 on the observation arm.

What Was Measured

PubMed files the paper under topics including Adenocarcinoma, Antineoplastic Agents, Hormonal, Chemotherapy, Adjuvant, Goserelin, Prognosis, Prostatic Neoplasms and Survival Analysis.

What This Means in Plain Language

The paper is a randomized study of Goserelin in 977 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1997 (Journal of clinical oncology : official journal of the American Society of Clinical Oncology), a journal based in United States.

More context: the Goserelin compound page, all human trials.